

COMPOSITIONS AND METHODS FOR THE TREATMENT
AND DIAGNOSIS OF CARDIOVASCULAR DISEASE

5

	1. INTRODUCTION	- 1 -
10	2. BACKGROUND OF THE INVENTION	- 1 -
	3. SUMMARY OF THE INVENTION	- 5 -
	4. DESCRIPTION OF THE FIGURES	- 11 -
15	5. DETAILED DESCRIPTION OF THE INVENTION	- 12 -
	5.1. IDENTIFICATION OF DIFFERENTIALLY EXPRESSED GENES	- 13 -
20	5.1.1. PARADIGMS FOR THE IDENTIFICATION OF DIFFERENTIALLY EXPRESSED GENES	- 14 -
	5.1.1.1. FOAM CELL PARADIGM - 1	- 15 -
25	5.1.1.2. FOAM CELL PARADIGM - 2	- 15 -
	5.1.1.3. FOAM CELL PARADIGM - 3	- 16 -
	5.1.1.4. IN VIVO MONOCYTE PARADIGM	- 16 -
30	5.1.1.5. ENDOTHELIAL CELL - IL-1 PARADIGM	- 16 -
	5.1.1.6. ENDOTHELIAL CELL - SHEAR STRESS PARADIGM	- 17 -
35	5.1.2. ANALYSIS OF PARADIGM MATERIAL	- 18 -

	5.2. IDENTIFICATION OF PATHWAY GENES	- 21 -
	5.3. CHARACTERIZATION OF DIFFERENTIALLY EXPRESSED AND PATHWAY GENES	- 23 -
5	5.4. DIFFERENTIALLY EXPRESSED AND PATHWAY GENES	- 26 -
	5.4.1. DIFFERENTIALLY EXPRESSED AND PATHWAY GENE SEQUENCES	- 26 -
10	5.4.2. DIFFERENTIALLY EXPRESSED AND PATHWAY GENE PRODUCTS	- 32 -
	5.4.3. DIFFERENTIALLY EXPRESSED OR PATHWAY GENE PRODUCT ANTIBODIES	- 38 -
15	5.4.4. CELL- AND ANIMAL-BASED MODEL SYSTEMS	- 40 -
	5.4.4.1. ANIMAL-BASED SYSTEMS	- 40 -
20	5.4.4.2. CELL-BASED ASSAYS	- 44 -
	5.5. SCREENING ASSAYS FOR COMPOUNDS THAT INTERACT WITH THE TARGET GENE PRODUCT AND/OR MODULATE TARGET GENE EXPRESSION	- 46 -
25	5.5.1. IN VITRO SCREENING ASSAYS FOR COMPOUNDS THAT BIND TO THE TARGET GENE PRODUCT	- 47 -
	5.5.2. ASSAYS FOR CELLULAR OR EXTRACELLULAR PROTEINS THAT INTERACT WITH THE TARGET GENE PRODUCT	- 49 -
30	5.5.3. ASSAYS FOR COMPOUNDS THAT INTERFERE WITH INTERACTION BETWEEN TARGET GENE PRODUCT AND OTHER COMPOUNDS	- 49 -
35		

20200204 14:29:07

	5.5.4. ASSAYS FOR AMELIORATION OF CARDIOVASCULAR DISEASE SYMPTOMS	- 55 -
	5.5.5. MONITORING OF EFFECTS DURING CLINICAL TRIALS	- 57 -
5	5.5.6. ASSAYS FOR COMPOUNDS THAT MODULATE EXPRESSION OF TARGET GENES	- 58 -
10	5.6. COMPOUNDS AND METHODS FOR TREATMENT OF CARDIOVASCULAR AND FIBROPROLIFERATIVE DISEASE	- 59 -
15	5.6.1. COMPOUNDS THAT INHIBIT EXPRESSION, SYNTHESIS OR ACTIVITY OF MUTANT TARGET GENE ACTIVITY	- 59 -
	5.6.1.1. INHIBITORY ANTISENSE, RIBOZYME, TRIPLE HELIX, AND GENE INACTIVATION APPROACHES	- 60 -
20	5.6.1.2. ANTIBODIES FOR TARGET GENE PRODUCTS	- 66 -
25	5.6.2. METHODS FOR RESTORING OR ENHANCING TARGET GENE ACTIVITY	- 67 -
30	5.7. PHARMACEUTICAL PREPARATIONS AND METHODS OF ADMINISTRATION	- 69 -
	5.7.1. EFFECTIVE DOSE	- 69 -
	5.7.2. FORMULATIONS AND USE	- 70 -
35	5.8. DIAGNOSIS OF CARDIOVASCULAR DISEASE ABNORMALITIES	- 71 -
	5.8.1. DETECTION OF FINGERPRINT GENE NUCLEIC ACIDS	- 72 -

	5.8.2. DETECTION OF FINGERPRINT GENE PEPTIDES	- 74 -
	5.8.3. IMAGING CARDIOVASCULAR DISEASE CONDITIONS	- 77 -
5	6. EXAMPLE: IDENTIFICATION OF GENES DIFFERENTIALLY EXPRESSED IN RESPONSE TO PARADIGM A: IN VITRO FOAM CELL PARADIGM	- 79 -
	6.1. MATERIALS AND METHODS	- 80 -
10	6.1.1. CELL ISOLATION AND CULTURING	- 80 -
	6.1.2. ANALYSIS OF PARADIGM MATERIAL	- 81 -
15	6.1.3. CHROMOSOMAL LOCALIZATION OF TARGET GENES	- 87 -
	6.2. RESULTS	- 87 -
20	7. EXAMPLE: IDENTIFICATION OF GENES DIFFERENTIALLY EXPRESSED IN RESPONSE TO PARADIGM D: ENDOTHELIAL CELL SHEAR STRESS	- 88 -
	7.1. MATERIALS AND METHODS	- 89 -
25	7.2. RESULTS	- 90 -
	8. EXAMPLE: USE OF GENES UNDER PARADIGM A AS SURROGATE MARKERS IN CLINICAL TRIALS	- 91 -
30	8.1. TREATMENT OF PATIENTS AND CELL ISOLATION	- 91 -
	8.2. ANALYSIS OF SAMPLES	- 92 -
35	9. EXAMPLE: IMAGING OF A CARDIOVASCULAR DISEASE CONDITION .	- 92 -

	9.1. MONOCLONAL CONJUGATED ANTIBODIES	- 92 -
	9.2. ADMINISTRATION AND DETECTION OF IMAGING AGENTS	- 92 -
	10. POLYCLONAL ANTIBODIES TO TARGET GENE PEPTIDE SEQUENCES .	- 93 -
5	11. EXAMPLE: THE RCHD534 AND FCHD540 GENE PRODUCTS INTERACT	- 93 -
	11.1. MATERIALS AND METHODS	- 94 -
10	11.1.1. YEAST STRAINS, MEDIA, AND MICROBIOLOGICAL TECHNIQUES	- 94 -
	11.1.2. PLASMID AND YEAST STRAIN CONSTRUCTION	- 94 -
15	11.1.4. PAPER FILTER BETA-GALACTOSIDASE ASSAYS	- 95 -
	11.2. RESULTS	- 96 -
20	11.2.1. STRONG PHYSICAL INTERACTION OF RCHD534 AND FCHD540 MEASURED BY TWO-HYBRID ASSAY	- 96 -
	11.2.2. IDENTIFICATION OF PROTEINS THAT PHYSICALLY INTERACT WITH FCHD540	- 97 -
25	11.2.3. RETRANSFORMATION AND SPECIFICITY TESTING OF TCHV03A AND TCHVR4A	- 97 -
30	11.3. FURTHER ANALYSIS OF RCHD534 AND FCHD540 FUNCTION	- 99 -
	11.3.1. CHROMOSOMAL LOCALIZATION	- 99 -
35	11.3.2. TISSUE EXPRESSION PATTERNS	- 99 -

	11.3.3. CELLULAR LOCALIZATION	- 100 -
	11.3.4. PROTEIN INTERACTIONS IN HUMAN CELLS	- 100 -
	11.3.5. EFFECT OF EXPRESSION ON TGF-B SIGNALLING	- 101 -
5		
	12. EXAMPLE: ANTISENSE AND RIBOZYME MOLECULES FOR INHIBITION OF RCHD534 AND FCHD540 EXPRESSION	- 102 -
	13. EXAMPLE: GENERATION OF TRANSGENIC KNOCKOUT RCHD534 MUTANT MICE	- 105 -
10		
	13.1. MATERIALS AND METHODS	- 105 -
	13.1.1. RCHD534 GENE TARGETING	- 105 -
15		
	13.1.2. GENERATION OF TRANSGENIC KNOCKOUT RCHD534 MUTANT MICE	- 106 -
	13.1.3. NORTHERN ANALYSIS.	- 106 -
20		
	13.1.4. LACZ STAINING.	- 106 -
	13.1.5. HISTOLOGY.	- 106 -
25		
	13.1.6. VASCULAR CONTRACTILITY STUDY.	- 106 -
	13.1.7. BLOOD PRESSURE MEASUREMENT.	- 107 -
	13.2. RESULTS	- 107 -
30		
	13.2.1. GENERATION OF TRANSGENIC KNOCKOUT RCHD534 MUTANT MICE	- 107 -
	13.2.2. LACZ STAINING OF RCHD534 MUTANT MICE	- 107 -
35		
	13.2.3. GENOTYPING OF PROGENY	- 108 -

	13.2.4. PHENOTYPIC CHARACTERISTICS OF RCHD534 MUTANT MICE	- 109 -
5	13.2.5. THE ROLE OF RCHD534 IN VASCULAR PHYSIOLOGY	- 110 -
10	13.2.6. THE INTERRELATIONSHIP BETWEEN THE PHENOTYPIC CONSEQUENCES OF THE RCHD534 MUTANT MICE AND TGF- β SUPERFAMILY SIGNALING	- 110 -
	14. EXAMPLE: THE RCHD534-LONG PROTEIN	- 111 -
15	14.1 IDENTIFICATION AND CHARACTERIZATION OF THE RCHD534-LONG SPLICEOFORM AND PROTEIN	- 112 -
20	14.2. TGF- β SIGNALLING INHIBITORY ACTIVITY OF THE RCHD534-LONG PROTEIN	- 113 -
	15. DEPOSIT OF MICROORGANISMS	- 114 -
25		
30		
35		